Navigation Links
Hyperfractionated RT improves local-regional control for patients with head and neck cancer

Fairfax, Va., May 1, 2014Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

This study, "Final Results of Local-Regional Control and Late Toxicity of RTOG 9003: A Randomized Trial of Altered Fractionation Radiation for Locally Advanced Head and Neck Cancer," is a multi-institutional, randomized Phase III trial of fractionation in locally advanced head and neck cancer. The study, the largest fractionation study performed to date, evaluated patients who received standard fractionation (SFX) compared to those that received HFX, accelerated fractionation with a split (AFX-S) or accelerated fractionation-continuous (AFX-C). Patients enrolled in RTOG 9003 were age 18 or older and had previously untreated, locally advanced squamous cell cancers of the oral cavity, oropharynx or supraglottic larynx in stage III or IV or stage II-IV carcinoma of the base of the tongue or hypopharynx. Patients with a prior (within five years) or synchronous malignancy other than nonmelanoma skin cancer were excluded. The trial accrued 1,076 eligible patients from September 30, 1991 to August 1, 1997.

Patients were randomized to four different treatment arms: SFX (2 Gy/fraction/day to 70 Gy in 35 fractions over seven weeks), HFX (1.2 Gy/fraction, twice daily, to 81.6 Gy over seven weeks), AFX-S (1.6 Gy/fraction, twice daily, to 67.2 Gy over six weeks, with a two-week break after 38.4 Gy) and AFX-C (total dose of 72 Gy delivered over six weeks in 1.8 Gy daily fractions and additional 1.5 Gy boost field in the afternoon during the last 12 days of treatment). All treatments were delivered five days a week, and twice-daily treatments had a minimum interfraction interval of six hours.

Local-regional failure was analyzed at two years, at five years and at last follow-up. As of October 1, 2012, the median follow-up was 14.1 years. Toxicity and disease recurrence assessment was conducted weekly while patients received radiation therapy; four months after treatment completion; every three months for one-and-a-half years; every four months between one-and-a-half and three years; every six months in years three to five; and then annually until death. Toxicities occurring ≤180 days from the start of radiation were considered acute, and those occurring >180 days after radiation therapy were considered late effects. At the time of this report's analysis in October 2012, 52.7 percent of patients (568) had experienced local-regional failure, with 97.4 percent (553) occurring within the first five years.

Secondary primary cancers were reported for 18.6 percent of patients (200), with 50 percent (100) reported within the first three years, and 75 percent (150) reported within the first 5.5 years. After 5.5 years post-treatment, the rates of secondary malignancies decreased to <1 percent per year. There were no significant differences in the rates of second malignancies among all four study arms.

At five years, the prevalence of grade 3, 4 or 5 toxicity, any feeding tube use after 180 days or feeding tube use at one year did not differ significantly when the SFX arm was compared to the three experimental arms. Grade 3, 4 or 5 toxicity tended to be decreased for patients treated over seven weeks compared to those treated over six weeks (9.0 percent vs. 16.7 percent, respectively), and 4.8 percent of disease-free patients treated with HFX had feeding tubes compared to 13.0 percent of patients treated with AFX-C.

At five-years post-treatment, patients in the HFX arm had the highest overall survival rates at 37.1 percent (HR 0.81, 95 percent CI), compared to 33.7 percent for the AFX-C arm, 29.3 percent for the SFX arm, 29.0 percent for the AFX-S arm.

"This study, one of only a few large studies to have follow-up beyond five years, demonstrates that patients who have head and neck cancers and who are being treated with radiation therapy alone have improved local-regional control and no increase in late toxicity when radiation therapy is delivered twice a day in two smaller doses which we call hyperfractionation," said Jonathan J. Beitler, MD, MBA, FASTRO, lead author of the study and professor of radiation oncology, otolaryngology and hematology/medical oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta. "The decrease in the rate of new cancers was unexpected; however, the large database and the long follow-up provided us with a window into information that had not previously been available about the long-term patterns of head and neck tumors and is particularly heartening. The results suggest that twice-daily radiation may improve cure and limit late side effects for patients. Twice-daily radiation might be worth considering in place of concurrent chemoradiotherapy for those patients who are at low risk for distant metastases and those patients who cannot tolerate systemic therapy."


Contact: Michelle Kirkwood
American Society for Radiation Oncology

Related medicine news :

1. Clinical insight improves treatment with new lung cancer drug
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Exercise improves quality of life during breast cancer treatment
4. Early treatment improves outcomes in rare, often undiagnosed form of encephalitis
5. NYUCNs Dr. Laura Wagner: Study finds accreditation improves safety culture at nursing homes
6. Brief training program improves resident physicians empathy with patients
7. A nurse practitioner-driven palliative care intervention improves cancer patients quality of life
8. Oxytocin improves brain function in children with autism
9. Nordic walking improves health of heart failure patients
10. Donor aortic graft improves reconstruction after partial laryngectomy
11. Vitamin C improves pulmonary function in newborns of pregnant smoking women
Post Your Comments:
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... Jobs in ... by healthcare professionals and offered by healthcare staffing agency Aureus Medical Group . ... the month of October 2015 among those searching for healthcare jobs through the company’s ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... opinion process, participated in the 61st annual Employee Benefits Conference. The Employee Benefits ... place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was held ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... and wellness consultation, has collaborated with Women’s Web – an online resource ... on topics on mental and emotional well-being relationship, life balance, stress, professional ...
(Date:11/25/2015)... Ill. (PRWEB) , ... November 25, 2015 , ... ... and potentially more aggressive than those found on mammography, according to a study ... findings of additional cancers not seen on mammography may necessitate a change in ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season is ... pleasing the palates of attendees is of the utmost importance. Whether you are ... get-together, give these recipes a try this holiday season. , Turkey Croquettes , ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... North Carolina , 26 november 2015 ... Inc. (AAIPharma/CML) kondigt de geplande investering aan ... uitbreiding van de laboratoria en het mondiale ... . De uitbreiding zal resulteren in extra ... wordt voldaan aan de groeiende behoeften van ...
(Date:11/26/2015)... 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ... kidney transplantation is expected to boost the market growth, as ... transplantation. --> 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ...
(Date:11/26/2015)... --> ... att använda SyMRI för att hitta optimal ... med multipel skleros (MS) eller hjärntumörmetastaser och ... för att kunna använda SyMRI Research Edition ... kan man generera flera konstrastbilder från en ...
Breaking Medicine Technology: